When correlating p63 expression with other genetic abnormalities and immunohistochemical biomarkers in DLBCL, we found that the p63+ group had higher frequencies of BCL6 translocation and CD30 positivity (21% compared with the 12% in p63− patients) (Table 1), as well as elevated expression levels of Bcl-6, IRF4/MUM-1, p21, MDM2, p16-INK4a, and Ki-67 (in ABC-DLBCL only); most of these associations were independent of TP53 mutation status (Fig 2B-L). Here, IRF4 is linked to diffuse large B-cell lymphoma.